Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Gram-Negative Infections | Current Treatment: Physician Insights | US | 2019

Login to access report north_east
Contact sales account_box

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) market. Most inpatients are successfully treated empirically with such agents, making it difficult for branded products like Merck & Co.’s Zerbaxa, Allergan’s Avycaz, Melinta’s Vabomere and Baxdela, Achaogen’s Zemdri, Tetraphase’s Xerava, or Paratek’s Nuzyra to gain uptake in earlier lines of therapy. However, rising antimicrobial resistance rates have created the need for safer products to effectively treat drug-resistant GNIs, and our primary market research shows that activity against key drug-resistant pathogens is an important driver of brand use in this market. Furthermore, hospital-based ID specialists report shifts in how they treat GNIs in response to the growing drug resistance.

QUESTIONS ANSWERED

  • What are the most prescribed first-, second-, and third-line therapies for inpatients with urinary tract infections, nosocomial pneumonia, or complicated intra-abdominal infections?
  • How are physicians approaching the treatment of infections caused by drug resistant pathogens?
  • Which clinical and nonclinical factors drive, and prevent, the prescribing of branded agents such as Zerbaxa, Avycaz, Vabomere, Zemdri, and Xerava?
  •  What will be the impact of the recent approval of Vabomere, Zemdri, Xerava, and other new agents? What will drive use of these therapies, and in which populations will they be used? Which current agents will be most affected?

PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use, so you can create specific messaging around these treatment dynamics in order to more effectively
increase or defend your market position.

GEOGRAPHIES: United States

PRIMARY RESEARCH: Survey of 100 U.S. hospital based, infectious disease and critical care specialists

KEY DRUGS COVERED: Avycaz, Zerbaxa, Vabomere, Zemdri, Xerava, Nuzyra, Baxdela, and other key GNI drugs

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east